Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anthera Pharmaceuticals, Inc. (ANTH)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
The Pennzoil Building 77002
Houston, TX, US
Houston, TX, US
CEO
Paul F. Truex
Website
anthera.com
IPO
2010-03-01
CIK 1316175 ISIN US03674U3005
Description
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.6K
Beta
-123.12
Float Shares
26.13M
Free Float %
99.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +9,900.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.86% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
0.04
+43,921.2%
DCF (Levered)
0.21
+213,552.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
40% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-78.14
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+84.1% ★ Q1'18: +88.4% (vs Q1'17)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'18: +1,003.1% (vs Q1'17)
-
Share dilution Biotechnology: -3.4%+99.1% Q1'18: +227.9% (vs Q1'17)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'18: 0.00× (vs Q1'17)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
3.19M
est: 1.38M (+130.9%)
|
145.0K
est: 122.5K (+18.4%)
|
—
|
—
est.
|
4.78M
est.
|
14.43M
est.
|
24.52M
est.
|
50.03M
est.
|
| EBITDA |
-34.96M
est: 275.9K (-12,769.0%)
|
-56.91M
est: -45.29M (-25.7%)
|
-26.59M
|
—
est.
|
956.4K
est.
|
2.88M
est.
|
4.90M
est.
|
10.01M
est.
|
| EBIT |
-35.24M
est: 275.9K (-12,872.3%)
|
-57.18M
est: -45.27M (-26.3%)
|
-26.87M
|
—
est.
|
956.4K
est.
|
2.88M
est.
|
4.90M
est.
|
10.01M
est.
|
| Net Income |
-34.91M
est: -89.14M (+60.8%)
|
-53.60M
est: -43.65M (-22.8%)
|
-16.94M
est: -30.55M (+44.6%)
|
-22.51M
est.
|
-15.83M
est.
|
-12.13M
est.
|
-8.12M
est.
|
1.54M
est.
|
| SGA |
7.57M
est: 22.55M (-66.4%)
|
11.07M
est: 2.00M (+452.9%)
|
7.94M
|
—
est.
|
78.16M
est.
|
235.78M
est.
|
400.84M
est.
|
817.70M
est.
|
| EPS |
-7.84
est: -8.67 (+9.6%)
|
-10.38
est: -12.26 (+15.4%)
|
-1.65
est: -2.97 (+44.5%)
|
-2.19
est.
|
-1.54
est.
|
-1.18
est.
|
-0.79
est.
|
0.15
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-31.95M
OE per share TTM
-2.46
Owner's Yield
-1,441,428.15%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
157.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alan E. Salzman | 6.46M | 29.60% | 6.46M | — | 6.46M | 10.00 | IN | Canada | 2010-03-12 | ↗ |
| 2 | VantagePoint Venture Associates IV, L.L.C. | 6.46M | 29.60% | 6.46M | — | 6.46M | 10.00 | OO | Delaware | 2010-03-12 | ↗ |
| 3 | VantagePoint Venture Partners IV (Q), L.P. | 5.84M | 26.80% | 5.84M | — | 5.84M | 10.00 | PN | Delaware | 2010-03-12 | ↗ |
| 4 | KEVIN C. TANG | 5.50M | 7.40% | — | 5.50M | — | — | IN | DELAWARE | 2012-07-30 | ↗ |
| 5 | TANG CAPITAL MANAGEMENT, LLC | 5.50M | 7.40% | — | 5.50M | — | — | OO | DELAWARE | 2012-07-30 | ↗ |
| 6 | TANG CAPITAL PARTNERS, LP | 5.50M | 7.40% | — | 5.50M | — | — | PN | DELAWARE | 2012-07-30 | ↗ |
| 7 | OrbiMed Advisors LLC | 4.76M | 13.95% | — | 4.76M | — | 10.00 | IA | Delaware | 2010-09-28 | ↗ |
| 8 | OrbiMed Capital GP IV LLC | 4.76M | 13.95% | — | 4.76M | — | 10.00 | OO | Delaware | 2010-09-28 | ↗ |
| 9 | Samuel D. Isaly | 4.76M | 13.95% | — | 4.76M | — | 10.00 | IN | United States | 2010-09-28 | ↗ |
| 10 | Peter Kolchinsky | 4.50M | 6.10% | 4.50M | — | 4.50M | — | IN | United States | 2012-07-27 | ↗ |
| 11 | RA Capital Management, LLC | 4.50M | 6.10% | 4.50M | — | 4.50M | — | IA | Massachusetts | 2012-07-27 | ↗ |
| 12 | RA Capital Healthcare Fund, L.P. | 2.68M | 3.60% | 2.68M | — | 2.68M | — | PN | Delaware | 2012-07-27 | ↗ |
| 13 | JG Asset, LLC | 1.91M | 5.74% | 1.91M | — | 1.91M | — | OO | Cayman Islands | 2010-10-01 | ↗ |
| 14 | Jacob Gottlieb | 1.91M | 5.74% | 1.91M | — | 1.91M | — | OO | Cayman Islands | 2010-10-01 | ↗ |
| 15 | Visium Asset Management, LP | 1.91M | 5.74% | 1.91M | — | 1.91M | — | OO | Cayman Islands | 2010-10-01 | ↗ |
| 16 | Visium Balanced Master Fund, Ltd | 1.91M | 5.74% | 1.91M | — | 1.91M | — | OO | Cayman Islands | 2010-10-01 | ↗ |
| 17 | 04-3519872 | 1.89M | 5.70% | — | — | — | — | IA | Delaware | 2011-02-10 | ↗ |
| 18 | HBM BioCapital (EUR) L.P. | 1.52M | 7.00% | — | 1.52M | — | — | PN | Cayman Islands, British West Indies | 2010-03-15 | ↗ |
| 19 | HBM BioCapital (USD) L.P. | 1.52M | 7.00% | — | 1.52M | — | — | PN | Cayman Islands, British West Indies | 2010-03-15 | ↗ |
| 20 | HBM BioCapital Ltd. | 1.52M | 7.00% | — | 1.52M | — | — | CO | Cayman Islands, British West Indies | 2010-03-15 | ↗ |
| 21 | Broadfin Capital, LLC | 1.30M | 5.70% | — | 1.30M | — | 1.30M | IA, OO | Delaware | 2014-10-03 | ↗ |
| 22 | Broadfin Healthcare Master Fund, Ltd. | 1.30M | 5.70% | — | 1.30M | — | 1.30M | CO | Delaware | 2014-10-03 | ↗ |
| 23 | Kevin Kotler | 1.30M | 5.70% | — | 1.30M | — | 1.30M | HC, IN | Delaware | 2014-10-03 | ↗ |
| 24 | Arthur M. Pappas | 1.16M | 5.40% | — | 1.16M | — | — | IN | DELAWARE | 2010-03-11 | ↗ |
| 25 | LLC | 1.16M | 5.40% | — | 1.16M | — | — | OO | DELAWARE | 2010-03-11 | ↗ |
| 26 | III, LP | 1.09M | 5.10% | — | 1.09M | — | — | PN | DELAWARE | 2010-03-11 | ↗ |
| 27 | Armistice Capital Master Fund Ltd. | 768.9K | 5.60% | — | 768.9K | — | 768.9K | CO | Delaware | 2017-11-03 | ↗ |
| 28 | Armistice Capital, LLC | 768.9K | 5.60% | — | 768.9K | — | 768.9K | IA, OO | Delaware | 2017-11-03 | ↗ |
| 29 | Steven Boyd | 768.9K | 5.60% | — | 768.9K | — | 768.9K | HC, IN | Delaware | 2017-11-03 | ↗ |
| 30 | VantagePoint Venture Partners IV, L.P. | 584.9K | 2.70% | 584.9K | — | 584.9K | 10.00 | PN | Delaware | 2010-03-12 | ↗ |
| 31 | LP | 67.9K | 0.30% | — | 67.9K | — | — | PN | DELAWARE | 2010-03-11 | ↗ |
| 32 | VantagePoint Venture Partners IV Principals Fund, L.P. | 21.3K | 0.10% | 21.3K | — | 21.3K | 10.00 | PN | Delaware | 2010-03-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-01-05 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 84,705 | 1.65 | 139.8K | 84,705 | — | ↗ |
| 2018-01-05 | TRUEX PAUL F | Director | A-Award | A | Stock Option (right to buy) | 84,705 | 1.65 | 139.8K | 84,705 | — | ↗ |
| 2018-01-05 | THOMPSON JOHN CRAIG | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,847,074 | 1.65 | 3.05M | 1,847,074 | — | ↗ |
| 2018-01-05 | Sager Philip | Director | A-Award | A | Stock Option (right to buy) | 84,705 | 1.65 | 139.8K | 84,705 | — | ↗ |
| 2018-01-05 | SHANAHAN WILLIAM R JR | Officer | A-Award | A | Stock Option (right to buy) | 567,876 | 1.65 | 937.0K | 567,876 | — | ↗ |
| 2018-01-05 | Mueller Brian | Director | A-Award | A | Stock Option (right to buy) | 84,705 | 1.65 | 139.8K | 84,705 | — | ↗ |
| 2018-01-05 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 84,705 | 1.65 | 139.8K | 84,705 | — | ↗ |
| 2018-01-05 | Furse Brent | Director | A-Award | A | Stock Option (right to buy) | 84,705 | 1.65 | 139.8K | 84,705 | — | ↗ |
| 2017-10-24 | Pennington James | Officer | — | D | Stock option (right to buy) | 4,746 | 2.08 | 9.9K | 0 | — | ↗ |
| 2017-09-20 | THOMPSON JOHN CRAIG | Director / Officer | P-Purchase | A | Common stock | 8,550 | 1.32 | 11.3K | 19,848 | — | ↗ |
| 2017-09-07 | TRUEX PAUL F | Director | P-Purchase | A | Common Stock | 5,000 | 1.34 | 6.7K | 16,793 | — | ↗ |
| 2017-09-07 | THOMPSON JOHN CRAIG | Director / Officer | P-Purchase | A | Common stock | 10,400 | 1.43 | 14.9K | 11,298 | — | ↗ |
| 2017-05-20 | THOMPSON JOHN CRAIG | Director / Officer | A-Award | A | Stock option (right to buy) | 81,250 | 1.63 | 132.4K | 81,250 | — | ↗ |
| 2017-05-20 | SHANAHAN WILLIAM R JR | Director / Officer | A-Award | A | Stock option (right to buy) | 75,000 | 1.63 | 122.3K | 75,000 | — | ↗ |
| 2017-05-20 | Olson Charles V | Officer | A-Award | A | Stock option (right to buy) | 43,750 | 1.63 | 71.3K | 43,750 | — | ↗ |
| 2017-05-20 | Dickinson Klara | Officer | A-Award | A | Stock option (right to buy) | 43,750 | 1.63 | 71.3K | 43,750 | — | ↗ |
| 2017-05-19 | TRUEX PAUL F | Director / Officer | J-Other | D | Stock option (right to buy) | 1,369 | 96.64 | 132.3K | 0 | — | ↗ |
| 2017-03-03 | THOMPSON JOHN CRAIG | Director / Officer | A-Award | A | Stock option (right to buy) | 100,000 | 0.64 | 64.0K | 100,000 | — | ↗ |
| 2016-12-31 | THOMPSON JOHN CRAIG | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-31 | Olson Charles V | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-08 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 83,910 | 2.00 | 167.8K | 83,910 | — | ↗ |
| 2016-12-08 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 83,910 | 2.00 | 167.8K | 83,910 | — | ↗ |
| 2016-12-06 | THOMPSON JOHN CRAIG | Director / Officer | A-Award | A | Stock option (right to buy) | 300,000 | 1.47 | 441.0K | 300,000 | — | ↗ |
| 2016-12-02 | TRUEX PAUL F | Director / Officer | J-Other | D | Stock option (right to buy) | 180,000 | 9.48 | 1.71M | 0 | — | ↗ |
| 2016-09-20 | TRUEX PAUL F | Officer | G-Gift | A | Common stock | 5,008 | 0.00 | — | 94,345 | — | ↗ |
| 2016-08-15 | SHANAHAN WILLIAM R JR | Officer | — | D | Stock option (right to buy) | 390,000 | 3.17 | 1.24M | 0 | — | ↗ |
| 2016-06-09 | TRUEX PAUL F | Officer | A-Award | A | Stock option (right to buy) | 300,000 | 3.52 | 1.06M | 300,000 | — | ↗ |
| 2016-06-09 | THOMPSON JOHN CRAIG | Officer | A-Award | A | Stock option (right to buy) | 170,000 | 3.52 | 598.4K | 170,000 | — | ↗ |
| 2016-06-09 | Olson Charles V | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 3.52 | 352.0K | 100,000 | — | ↗ |
| 2016-06-09 | Dickinson Klara | Officer | A-Award | A | Stock option (right to buy) | 105,000 | 3.52 | 369.6K | 105,000 | — | ↗ |
| 2016-04-27 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 41,379 | 3.80 | 157.2K | 41,379 | — | ↗ |
| 2016-04-27 | Sager Philip | Director | A-Award | A | Stock Option (right to buy) | 41,379 | 3.80 | 157.2K | 41,379 | — | ↗ |
| 2016-04-27 | Mueller Brian | Director | A-Award | A | Stock Option (right to buy) | 41,379 | 3.80 | 157.2K | 41,379 | — | ↗ |
| 2016-04-27 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 62,069 | 3.80 | 235.9K | 62,069 | — | ↗ |
| 2016-04-27 | Furse Brent | Director | — | D | Stock option (right to buy) | 33,670 | 3.80 | 127.9K | 0 | — | ↗ |
| 2016-04-27 | ENGLE STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 41,379 | 3.80 | 157.2K | 41,379 | — | ↗ |
| 2016-04-01 | Pennington James | Officer | — | D | Common Stock | 0 | 0.00 | — | 17,688 | — | ↗ |
| 2016-02-12 | TRUEX PAUL F | Officer | A-Award | A | Stock option (right to buy) | 15,816 | 2.86 | 45.2K | 15,816 | — | ↗ |
| 2016-02-12 | Olson Charles V | Officer | A-Award | A | Stock option (right to buy) | 5,626 | 2.86 | 16.1K | 5,626 | — | ↗ |
| 2016-02-12 | Hislop Colin | Officer | A-Award | A | Stock Option (right to buy) | 10,848 | 2.86 | 31.0K | 10,848 | — | ↗ |
| 2016-02-12 | Dickinson Klara | Officer | A-Award | A | Stock Option (right to buy) | 8,395 | 2.86 | 24.0K | 8,395 | — | ↗ |
| 2016-01-07 | THOMPSON JOHN CRAIG | Officer | — | D | Stock option (right to buy) | 380,000 | 3.70 | 1.41M | 0 | — | ↗ |
| 2016-01-05 | Olson Charles V | Officer | — | D | Common Stock | 0 | 0.00 | — | 7,963 | — | ↗ |
| 2015-12-31 | TRUEX PAUL F | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-12-31 | Dickinson Klara | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-12-23 | Mueller Brian | Director | M-Exempt | A | Common stock | 10,000 | 2.89 | 28.9K | 10,000 | — | ↗ |
| 2015-11-13 | Hislop Colin | Officer | M-Exempt | A | Common Stock | 12,500 | 1.61 | 20.1K | 31,647 | — | ↗ |
| 2015-11-11 | Hislop Colin | Officer | S-Sale | D | Common Stock | 5,000 | 5.38 | 26.9K | 19,147 | — | ↗ |
| 2015-10-12 | ODINK DEBRA | Officer | S-Sale | D | Common Stock | 1,205 | 6.15 | 7.4K | 7,896 | — | ↗ |
| 2015-09-17 | TRUEX PAUL F | Officer | A-Award | A | Stock option (right to buy) | 170,000 | 9.48 | 1.61M | 170,000 | — | ↗ |
| 2015-09-17 | ODINK DEBRA | Officer | A-Award | A | Stock option (right to buy) | 30,000 | 9.48 | 284.4K | 30,000 | — | ↗ |
| 2015-09-17 | Hislop Colin | Officer | A-Award | A | Stock option (right to buy) | 30,000 | 9.48 | 284.4K | 30,000 | — | ↗ |
| 2015-09-17 | Dickinson Klara | Officer | A-Award | A | Stock option (right to buy) | 50,000 | 9.48 | 474.0K | 50,000 | — | ↗ |
| 2015-05-21 | ZWEIFACH SANFORD S | Director | A-Award | A | Stock Option (right to buy) | 28,846 | 4.75 | 137.0K | 28,846 | — | ↗ |
| 2015-05-21 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 28,846 | 4.75 | 137.0K | 28,846 | — | ↗ |
| 2015-05-21 | Sager Philip | Director | A-Award | A | Stock Option (right to buy) | 28,846 | 4.75 | 137.0K | 28,846 | — | ↗ |
| 2015-05-21 | Mueller Brian | Director | A-Award | A | Stock Option (right to buy) | 28,846 | 4.75 | 137.0K | 28,846 | — | ↗ |
| 2015-05-21 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 43,269 | 4.75 | 205.5K | 43,269 | — | ↗ |
| 2015-05-21 | ENGLE STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 28,846 | 4.75 | 137.0K | 28,846 | — | ↗ |
| 2015-05-21 | Dickinson Klara | Officer | — | D | Stock option (right to buy) | 50,000 | 1.61 | 80.5K | 0 | — | ↗ |
| 2014-12-31 | TRUEX PAUL F | Officer | G-Gift | A | Common Stock | 12,500 | 0.00 | — | 89,337 | — | ↗ |
| 2014-12-30 | ZWEIFACH SANFORD S | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.61 | 20.1K | 12,500 | — | ↗ |
| 2014-12-30 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.61 | 20.1K | 12,500 | — | ↗ |
| 2014-12-30 | TRUEX PAUL F | Officer | A-Award | A | Stock option (right to buy) | 330,000 | 1.61 | 531.3K | 330,000 | — | ↗ |
| 2014-12-30 | Sager Philip | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.61 | 24.2K | 12,500 | — | ↗ |
| 2014-12-30 | ODINK DEBRA | Officer | G-Gift | D | Common Stock | 1,364 | 0.00 | — | 9,101 | — | ↗ |
| 2014-12-30 | Mueller Brian | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.61 | 20.1K | 12,500 | — | ↗ |
| 2014-12-30 | Hislop Colin | Officer | A-Award | A | Stock option (right to buy) | 120,000 | 1.61 | 193.2K | 120,000 | — | ↗ |
| 2014-12-30 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 16,250 | 1.61 | 26.2K | 16,250 | — | ↗ |
| 2014-12-30 | ENGLE STEVEN B | Director | A-Award | A | Stock option (right to buy) | 12,500 | 1.61 | 20.1K | 12,500 | — | ↗ |
| 2014-07-29 | Mueller Brian | Director | M-Exempt | D | Stock Option (right to buy) | 10,000 | 2.89 | 28.9K | 2,500 | — | ↗ |
| 2014-06-30 | TRUEX PAUL F | Officer | J-Other | D | Common Stock | 14,709 | 0.00 | — | 14,709 | — | ↗ |
| 2014-06-18 | Mueller Brian | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-13 | ZWEIFACH SANFORD S | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 3.35 | 41.9K | 12,500 | — | ↗ |
| 2014-06-13 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 3.35 | 41.9K | 12,500 | — | ↗ |
| 2014-06-13 | Sager Philip | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-13 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 3.35 | 41.9K | 12,500 | — | ↗ |
| 2014-06-13 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 15,625 | 3.35 | 52.3K | 15,625 | — | ↗ |
| 2014-06-13 | ENGLE STEVEN B | Director | A-Award | A | Stock option (right to buy) | 12,500 | 3.35 | 41.9K | 12,500 | — | ↗ |
| 2014-03-25 | TRUEX PAUL F | Officer | A-Award | A | Common Stock | 6,250 | 3.30 | 20.6K | 597,787 | — | ↗ |
| 2014-03-25 | ODINK DEBRA | Officer | F-InKind | D | Common Stock | 2,783 | 3.30 | 9.2K | 6,601 | — | ↗ |
| 2014-03-25 | Hislop Colin | Officer | A-Award | A | Common Stock | 3,864 | 0.00 | — | 24,147 | — | ↗ |
| 2014-03-25 | ENGLE STEVEN B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-06-30 | TRUEX PAUL F | Officer | A-Award | A | Common Stock | 6,250 | 3.30 | 20.6K | 80,190 | — | ↗ |
| 2013-06-30 | ODINK DEBRA | Officer | F-InKind | D | Common Stock | 2,248 | 0.49 | 1.1K | 75,074 | — | ↗ |
| 2013-06-24 | Thompson David E. | Director | P-Purchase | A | Common Stock | 100,000 | 0.53 | 53.0K | 128,201 | — | ↗ |
| 2013-05-31 | DZIURZYNSKI BOGDAN | Director | P-Purchase | A | Common Stock | 10,000 | 0.59 | 5.9K | 10,000 | — | ↗ |
| 2013-05-21 | TRUEX PAUL F | Officer | G-Gift | D | Common Stock | 100,000 | 0.00 | — | 591,537 | — | ↗ |
| 2013-05-17 | ZWEIFACH SANFORD S | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.61 | 61.0K | 100,000 | — | ↗ |
| 2013-05-17 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.61 | 61.0K | 100,000 | — | ↗ |
| 2013-05-17 | TRUEX PAUL F | Officer | A-Award | A | Stock option (right to buy) | 5,400,000 | 0.61 | 3.29M | 5,400,000 | — | ↗ |
| 2013-05-17 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.61 | 61.0K | 100,000 | — | ↗ |
| 2013-05-17 | ODINK DEBRA | Officer | A-Award | A | Stock option (right to buy) | 1,400,000 | 0.61 | 854.0K | 1,400,000 | — | ↗ |
| 2013-05-17 | LOWE CHRISTOPHER P. | Officer | A-Award | A | Stock option (right to buy) | 1,300,000 | 0.61 | 793.0K | 1,300,000 | — | ↗ |
| 2013-05-17 | Hislop Colin | Officer | A-Award | A | Stock option (right to buy) | 1,300,000 | 0.61 | 793.0K | 1,300,000 | — | ↗ |
| 2013-05-17 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.61 | 76.3K | 125,000 | — | ↗ |
| 2013-05-17 | HEALY JAMES | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.61 | 61.0K | 100,000 | — | ↗ |
| 2013-05-17 | DZIURZYNSKI BOGDAN | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.61 | 61.0K | 100,000 | — | ↗ |
| 2013-03-25 | ZWEIFACH SANFORD S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-03-25 | TRUEX PAUL F | Officer | A-Award | A | Common Stock | 135,644 | 0.00 | — | 135,644 | — | ↗ |
| 2013-03-25 | ODINK DEBRA | Officer | A-Award | A | Common Stock | 49,519 | 0.00 | — | 77,322 | — | ↗ |
| 2013-03-25 | LOWE CHRISTOPHER P. | Officer | A-Award | A | Common Stock | 67,579 | 0.00 | — | 108,915 | — | ↗ |
| 2013-03-25 | Hislop Colin | Officer | A-Award | A | Common Stock | 59,132 | 0.00 | — | 144,091 | — | ↗ |
| 2013-01-30 | ORBIMED ADVISORS LLC | Director | P-Purchase | A | Common Stock | 5,700,000 | 0.66 | 3.76M | 7,462,000 | — | ↗ |
| 2013-01-25 | ORBIMED ADVISORS LLC | Director | P-Purchase | A | Common Stock | 1,762,000 | 0.65 | 1.14M | 1,762,000 | — | ↗ |
| 2013-01-10 | ODINK DEBRA | Officer | G-Gift | A | Common Stock | 4,009 | 0.00 | — | 99,937 | — | ↗ |
| 2013-01-07 | TRUEX PAUL F | Officer | G-Gift | A | Common stock | 66,412 | 0.00 | — | 691,537 | — | ↗ |
| 2013-01-03 | TRUEX PAUL F | Officer | F-InKind | D | Common Stock | 17,454 | 0.69 | 12.0K | 66,412 | — | ↗ |
| 2013-01-03 | ODINK DEBRA | Officer | F-InKind | D | Common Stock | 3,409 | 0.69 | 2.4K | 31,812 | — | ↗ |
| 2013-01-03 | LOWE CHRISTOPHER P. | Officer | F-InKind | D | Common stock | 8,660 | 0.69 | 6.0K | 41,336 | — | ↗ |
| 2013-01-03 | KILFOIL GEORGINA | Officer | F-InKind | D | Common Stock | 2,410 | 0.69 | 1.7K | 30,035 | — | ↗ |
| 2013-01-03 | Hislop Colin | Officer | F-InKind | D | Common Stock | 4,560 | 0.69 | 3.1K | 84,959 | — | ↗ |
| 2012-06-30 | ODINK DEBRA | Officer | F-InKind | D | Common Stock | 1,838 | 0.69 | 1.3K | 24,821 | — | ↗ |
| 2012-06-30 | KILFOIL GEORGINA | Officer | F-InKind | D | Common Stock | 2,068 | 0.69 | 1.4K | 24,601 | — | ↗ |
| 2012-06-29 | TRUEX PAUL F | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-06-29 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 1,283,300 | 0.73 | 942.1K | 0 | — | ↗ |
| 2012-06-29 | HENNEY CHRISTOPHER S | Director | P-Purchase | A | Common Stock | 100,000 | 0.75 | 74.9K | 202,429 | — | ↗ |
| 2012-05-08 | Thompson Peter A. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.79 | 21.5K | 12,000 | — | ↗ |
| 2012-05-08 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.79 | 21.5K | 12,000 | — | ↗ |
| 2012-05-08 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.79 | 21.5K | 12,000 | — | ↗ |
| 2012-05-08 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.79 | 26.9K | 15,000 | — | ↗ |
| 2012-05-08 | HEALY JAMES | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.79 | 21.5K | 12,000 | — | ↗ |
| 2012-05-08 | DZIURZYNSKI BOGDAN | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.79 | 21.5K | 12,000 | — | ↗ |
| 2012-03-30 | TRUEX PAUL F | Director / Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 2.21 | 386.8K | 175,000 | — | ↗ |
| 2012-03-30 | ODINK DEBRA | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 2.21 | 353.6K | 160,000 | — | ↗ |
| 2012-03-30 | LOWE CHRISTOPHER P. | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.21 | 176.8K | 80,000 | — | ↗ |
| 2012-03-30 | KILFOIL GEORGINA | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 2.21 | 132.6K | 60,000 | — | ↗ |
| 2012-03-30 | Hislop Colin | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.21 | 176.8K | 80,000 | — | ↗ |
| 2012-03-30 | DZIURZYNSKI BOGDAN | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 2.21 | 55.3K | 25,000 | — | ↗ |
| 2012-03-22 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 1,306,700 | 2.40 | 3.14M | 1,283,300 | — | ↗ |
| 2012-03-21 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 125,000 | 2.87 | 358.3K | 2,590,000 | — | ↗ |
| 2012-03-20 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 116,800 | 2.90 | 338.6K | 2,715,000 | — | ↗ |
| 2012-03-01 | ODINK DEBRA | Officer | S-Sale | D | Common Stock | 2,000 | 6.57 | 13.1K | 26,659 | — | ↗ |
| 2012-03-01 | DZIURZYNSKI BOGDAN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-02-23 | Hislop Colin | Officer | M-Exempt | A | Common Stock | 40,000 | 0.26 | 10.4K | 79,519 | — | ↗ |
| 2012-02-15 | TRUEX PAUL F | Director / Officer | S-Sale | D | Common stock | 15,000 | 7.84 | 117.6K | 625,125 | — | ↗ |
| 2012-02-06 | TRUEX PAUL F | Director / Officer | A-Award | A | Common stock | 37,984 | 0.00 | — | 79,755 | — | ↗ |
| 2012-02-06 | ODINK DEBRA | Officer | A-Award | A | Common Stock | 7,418 | 0.00 | — | 28,659 | — | ↗ |
| 2012-02-06 | LOWE CHRISTOPHER P. | Officer | A-Award | A | Common Stock | 18,845 | 0.00 | — | 49,996 | — | ↗ |
| 2012-02-06 | KILFOIL GEORGINA | Officer | A-Award | A | Common Stock | 5,243 | 0.00 | — | 24,513 | — | ↗ |
| 2012-02-06 | Hislop Colin | Officer | A-Award | A | Common Stock | 9,923 | 0.00 | — | 39,519 | — | ↗ |
| 2012-02-03 | Hislop Colin | Officer | S-Sale | D | Common Stock | 30,000 | 8.20 | 246.0K | 27,967 | — | ↗ |
| 2012-02-01 | ODINK DEBRA | Officer | S-Sale | D | Common Stock | 2,000 | 7.67 | 15.3K | 21,241 | — | ↗ |
| 2012-02-01 | LOWE CHRISTOPHER P. | Officer | S-Sale | D | Common stock | 15,000 | 7.66 | 114.9K | 31,151 | — | ↗ |
| 2012-01-31 | TRUEX PAUL F | Director / Officer | M-Exempt | A | Common stock | 20,000 | 0.26 | 5.2K | 640,125 | — | ↗ |
| 2012-01-28 | HEALY JAMES | Director | M-Exempt | D | Common Stock | 12,000 | 4.19 | 50.3K | 32,443 | — | ↗ |
| 2012-01-27 | TRUEX PAUL F | Director / Officer | G-Gift | D | Common stock | 7,000 | 0.00 | — | 620,125 | — | ↗ |
| 2012-01-17 | TRUEX PAUL F | Director / Officer | S-Sale | D | Common stock | 15,000 | 6.75 | 101.3K | 627,125 | — | ↗ |
| 2012-01-10 | ODINK DEBRA | Officer | S-Sale | D | Common Stock | 800 | 6.51 | 5.2K | 23,241 | — | ↗ |
| 2012-01-06 | ODINK DEBRA | Officer | S-Sale | D | Common Stock | 1,200 | 6.50 | 7.8K | 24,441 | — | ↗ |
| 2011-12-30 | SOFINNOVA VENTURE PARTNERS VI L P | 10% Owner | S-Sale | D | Common Stock | 20,630 | 6.23 | 128.4K | 3,298,684 | — | ↗ |
| 2011-12-30 | HEALY JAMES | Director / 10% Owner | S-Sale | D | Common Stock | 280 | 6.23 | 1.7K | 44,969 | — | ↗ |
| 2011-12-22 | SOFINNOVA VENTURE PARTNERS VI L P | 10% Owner | S-Sale | D | Common Stock | 20,630 | 6.22 | 128.4K | 3,319,314 | — | ↗ |
| 2011-12-22 | HEALY JAMES | Director / 10% Owner | S-Sale | D | Common Stock | 20,630 | 6.22 | 128.4K | 3,319,314 | — | ↗ |
| 2011-12-21 | SOFINNOVA VENTURE PARTNERS VI L P | 10% Owner | S-Sale | D | Common Stock | 20,630 | 6.51 | 134.3K | 3,339,944 | — | ↗ |
| 2011-12-21 | HEALY JAMES | Director / 10% Owner | S-Sale | D | Common Stock | 20,630 | 6.51 | 134.3K | 3,339,944 | — | ↗ |
| 2011-12-15 | TRUEX PAUL F | Director / Officer | S-Sale | D | Common stock | 15,000 | 6.34 | 95.1K | 642,125 | — | ↗ |
| 2011-12-13 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 16,200 | 6.50 | 105.3K | 2,831,800 | — | ↗ |
| 2011-12-09 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 40,000 | 6.75 | 270.0K | 2,848,000 | — | ↗ |
| 2011-11-18 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 3,000 | 6.50 | 19.5K | 2,888,000 | — | ↗ |
| 2011-11-17 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 24,000 | 6.67 | 160.1K | 2,891,000 | — | ↗ |
| 2011-11-16 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 25,000 | 6.87 | 171.8K | 2,915,000 | — | ↗ |
| 2011-11-15 | TRUEX PAUL F | Director / Officer | G-Gift | A | Common Stock | 50,000 | 0.00 | — | 687,125 | — | ↗ |
| 2011-11-15 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 50,000 | 6.93 | 346.5K | 2,940,000 | — | ↗ |
| 2011-11-14 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 5,000 | 6.95 | 34.8K | 2,990,000 | — | ↗ |
| 2011-11-11 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 5,000 | 7.14 | 35.7K | 2,995,000 | — | ↗ |
| 2011-11-08 | Hislop Colin | Officer | M-Exempt | D | Stock Option | 15,000 | 0.26 | 3.9K | 90,447 | — | ↗ |
| 2011-11-07 | Thompson David E. | Director | G-Gift | D | Common Stock | 3,800 | 0.00 | — | 7,758 | — | ↗ |
| 2011-11-03 | LOWE CHRISTOPHER P. | Officer | S-Sale | D | Common Stock | 15,000 | 6.88 | 103.2K | 46,151 | — | ↗ |
| 2011-10-25 | LOWE CHRISTOPHER P. | Officer | S-Sale | D | Common Stock | 4,637 | 7.07 | 32.8K | 0 | — | ↗ |
| 2011-10-21 | TRUEX PAUL F | Director / Officer | S-Sale | D | Common Stock | 11,879 | 6.25 | 74.2K | 637,125 | — | ↗ |
| 2011-10-18 | TRUEX PAUL F | Director / Officer | S-Sale | D | Common Stock | 6,745 | 6.25 | 42.2K | 660,360 | — | ↗ |
| 2011-08-08 | TRUEX PAUL F | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 50,000 | 0.26 | 13.0K | 282,826 | — | ↗ |
| 2011-08-08 | LOWE CHRISTOPHER P. | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 1.34 | 13.4K | 64,886 | — | ↗ |
| 2011-08-03 | LOWE CHRISTOPHER P. | Officer | S-Sale | D | Common Stock | 14,600 | 6.88 | 100.4K | 51,151 | — | ↗ |
| 2011-08-02 | LOWE CHRISTOPHER P. | Officer | S-Sale | D | Common Stock | 4,700 | 7.28 | 34.2K | 4,937 | — | ↗ |
| 2011-07-15 | TRUEX PAUL F | Director / Officer | S-Sale | D | Common Stock | 15,000 | 7.95 | 119.3K | 667,125 | — | ↗ |
| 2011-07-12 | Hislop Colin | Officer | M-Exempt | D | Stock Option (right to buy) | 15,000 | 0.26 | 3.9K | 105,447 | — | ↗ |
| 2011-07-07 | VANTAGEPOINT VENTURE ASSOCIATES IV LLC | 10% Owner | M-Exempt | A | Common Stock | 9,248 | 1.34 | 12.4K | 5,347,213 | — | ↗ |
| 2011-06-30 | Thompson Peter A. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 8.17 | 204.3K | 25,000 | — | ↗ |
| 2011-06-30 | Thompson David E. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 8.17 | 98.0K | 12,000 | — | ↗ |
| 2011-06-30 | TRUEX PAUL F | Director / Officer | F-InKind | D | Common Stock | 48,500 | 8.17 | 396.2K | 40,512 | — | ↗ |
| 2011-06-30 | Santel Donald J | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 8.17 | 98.0K | 12,000 | — | ↗ |
| 2011-06-30 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 8.17 | 98.0K | 12,000 | — | ↗ |
| 2011-06-30 | ODINK DEBRA | Officer | F-InKind | D | Common Stock | 3,670 | 8.17 | 30.0K | 25,641 | — | ↗ |
| 2011-06-30 | LOWE CHRISTOPHER P. | Officer | F-InKind | D | Common Stock | 23,500 | 8.17 | 192.0K | 65,751 | — | ↗ |
| 2011-06-30 | KILFOIL GEORGINA | Officer | F-InKind | D | Common Stock | 5,625 | 8.17 | 46.0K | 16,875 | — | ↗ |
| 2011-06-30 | Hislop Colin | Officer | F-InKind | D | Common Stock | 17,500 | 8.17 | 143.0K | 42,967 | — | ↗ |
| 2011-06-30 | HENNEY CHRISTOPHER S | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 8.17 | 122.6K | 15,000 | — | ↗ |
| 2011-06-30 | HEALY JAMES | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 8.17 | 98.0K | 12,000 | — | ↗ |
| 2011-06-29 | Hislop Colin | Officer | M-Exempt | A | Common Stock | 10,000 | 0.26 | 2.6K | 60,062 | — | ↗ |
| 2011-06-21 | LOWE CHRISTOPHER P. | Officer | M-Exempt | A | Common Stock | 17,080 | 1.51 | 25.8K | 87,645 | — | ↗ |
| 2011-06-16 | VANTAGEPOINT VENTURE ASSOCIATES IV LLC | 10% Owner | S-Sale | D | Common Stock | 2,809 | 8.67 | 24.4K | 4,836,202 | — | ↗ |
| 2011-06-15 | TRUEX PAUL F | Director / Officer | S-Sale | D | Common Stock | 15,000 | 8.30 | 124.5K | 682,125 | — | ↗ |
| 2011-06-14 | VANTAGEPOINT VENTURE ASSOCIATES IV LLC | 10% Owner | S-Sale | D | Common Stock | 634 | 8.81 | 5.6K | 4,839,011 | — | ↗ |
| 2011-06-13 | VANTAGEPOINT VENTURE ASSOCIATES IV LLC | 10% Owner | S-Sale | D | Common Stock | 118 | 8.80 | 1.0K | 484,496 | — | ↗ |
| 2011-06-10 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 30,000 | 8.18 | 245.4K | 3,000,000 | — | ↗ |
| 2011-06-09 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 37,000 | 8.11 | 300.1K | 3,030,000 | — | ↗ |
| 2011-06-08 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 33,000 | 8.02 | 264.7K | 3,067,000 | — | ↗ |
| 2011-05-31 | TRUEX PAUL F | Director / Officer | G-Gift | D | Common Stock | 5,122 | 0.00 | — | 86,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
26.18M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| May Liu | Senior Vice President of Finance & Administration and Principal Accounting Officer | 373.4K | female |
| Paul F. Truex | Executive Chairman | 100.0K | male |
| Joshua Caldwell | Chief Liquidating Officer | — | — |
| Paul Adams | Senior Vice President of Global Regulatory Affairs and Compliance | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
